Findings, Presented at Annual American Society of Pain & Neuroscience Conference, Demonstrate Significant and Durable Relief of Chronic Vertebrogenic Low...
Neurovations Research proud to be a part of study that released first positive results to slow Alzheimer's DiseaseNAPA, CA /...
Policy Updates Impact Nationwide Commercial Plans for 16.8 Million Covered LivesMALVERN, Pa., July 19, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc....
Vivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting Progress of N3pE-Amyloid-targeting Small Molecule Varoglutamstat in Alzheimer’s Disease Small molecule varoglutamstat,...
VANCOUVER, British Columbia, July 14, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or...
Dr. Adrienne Graves to join Board of DirectorsBEDFORD, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a...
Multi-year drug discovery collaboration to identify small molecule cGAS inhibitors for treating neurodegenerative diseases including Alzheimer’sROME, July 12, 2023 (GLOBE...
Award Recognizes Efforts to Raise Awareness Around Non-Drug Depression TreatmentMALVERN, Pa., July 11, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:...
Experienced Pharma Industry Clinical Operations Leader to Spearhead Development of Cellular Therapy ProgramsMIAMI, July 11, 2023 (GLOBE NEWSWIRE) -- Longeveron...
Multisystem Purchases by Asha Neuromodulation Clinics (ANC) Allow for Increased Access to Deep TMS™BURLINGTON, Mass. and JERUSALEM, July 11, 2023...
EVOTEC AND BRISTOL MYERS SQUIBB ENTER EXCLUSIVE GLOBAL LICENCE AGREEMENT FOR SELECTED PROGRAMMES DEVELOPED AND PROGRESSED IN THE COLLABORATIONSELECTED PROGRAMMES...
Vital breakthrough for Alzheimer's patients worldwide with Eisai's Leqembi FDA approval; Cognetivity Neurosciences' AI CognICA technology poised to play pivotal...
Company to voluntarily delist from the Toronto Stock Exchange (TSX)Last trading day on TSX will be July 21, 2023 TORONTO, Ontario...
Approval by UKCA Empowers UK Physicians to Advance Care of Treatment Resistant Depression, Obsessive Compulsive Disorder, and Anxious Depression with...
NEW YORK, July 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...
ROCKAWAY, N.J., July 06, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced...
NEW YORK and LONDON, July 05, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing...
TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 30, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (NASDAQ: PMN), a biotechnology...
Financing represents minimum cash required to consummate the business combination and bridge AEON through key episodic migraine data readoutIRVINE, Calif.,...
Trial met primary endpoint with a statistically significant higher percentage of patients achieving a clinically meaningful cholestasis response compared to...